49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Conference

related documents

• A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies  Conference Paper
• A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer  Conference Paper
• A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)  Conference Paper
• A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.  Conference Paper
• A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.  Conference Paper
• A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21)  Conference Paper
• A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial  Conference Paper
• A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).  Conference Paper
• A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20.  Conference Paper
• Bowel obstruction with stage IV cancer: The benefit of introduction of formal palliative care service.  Conference Paper
• Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements  Conference Paper
• Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.  Conference Paper
• Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.  Conference Paper
• Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC.  Conference Paper
• Clinical management and resolution of stomatitis in BOLERO-2.  Conference Paper
• Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.  Conference Paper
• Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).  Conference Paper
• Development of a practice consensus statement of the management of locally advanced breast cancer: Expert consensus and systematic review.  Conference Paper
• Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC)  Conference Paper
• Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial  Conference Paper
• Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM)  Conference Paper
• Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.  Conference Paper
• First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.  Conference Paper
• Identification of knowledge translation opportunities in the treatment of locally advanced breast cancer: Results of a national survey of physicians  Conference Paper
• Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.  Conference Paper
• Impact of wait times on survival of women with uterine cancer.  Conference Paper
• Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.  Conference Paper
• Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy  Conference Paper
• NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).  Conference Paper
• Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC)  Conference Paper
• Ovarian cancer distribution of histology, stage, and screening performance  Conference Paper
• Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.  Conference Paper
• Perioperative epidural analgesia and recurrence-free survival for ovarian cancer surgery: A retrospective analysis.  Conference Paper
• Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr plus T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041)  Conference Paper
• Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies.  Conference Paper
• Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369.  Conference Paper
• Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.  Conference Paper
• Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program  Conference Paper
• Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC).  Conference Paper
• Results from a structured interprofessional palliative care rehabilitation program in oncology.  Conference Paper
• Screening for Lynch syndrome in unselected women with endometrial cancer  Conference Paper
• Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada  Conference Paper
• Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up  Conference Paper
• The effect of surgery type on survival and recurrence in very young women with breast cancer.  Conference Paper
• The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada  Conference Paper
• The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists.  Conference Paper
• Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab.  Conference Paper
• Toward integration of palliative care into cancer care: A study on profile of psychosocial and clinical complications among attendees of a Nigerian oncological center.  Conference Paper
• Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study  Conference Paper